166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo

166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo

Bibliographic Details
Main Authors: Gabriel Helmlinger, Rachel Burga, Stanley Tam, Mithun Khattar, Scott Lajoie, Kyle Pedro, Colleen Foley, Alonso Villasmil Ocando, Jack Tremblay, Benjamin Primack, Meghan Langley, Dan Thornton, Emily Brideau, Theresa Ross, Gwen Wilmes, Sunandan Saha, Jeremy Tchaicha, Dhruv Sethi, Michelle Ols, Gary Vanasse, Shyam Subramanian, Jan ter Meulen
Format: Article
Language:English
Published: BMJ Publishing Group 2021-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items